Hollyhigh Capital is a leading Chinese investment bank which focuses on enterprise M&A across the healthcare industry with the core businesses of M&A/sales/financing consultation, buyout funds, cross-border M&A, etc. It aims to develop into a leading international investment bank that provides full-service for comprehensive healthcare enterprises’ M&A and upgrades. 北京东方高圣控股股份有限公司www.hollyhigh.cn 是中国领先的专注于大健康领域并购的投资银行,公司核心业务是并购/出售/融资顾问、并购基金、跨境并购等,致力于成为全面服务大健康企业并购升级的国际领先投行。 Most of Hollyhigh’s core team members graduated from top Chinese and International academies such as Tsinghua, Peking University School of Pharmaceutical Sciences (SPS) China Pharmaceutical University and Imperial College London. Mr. James Chen, the company’s founder, graduated from Tsinghua University School of Economics and Management and was rated as one of the most influential investment bankers by “Talents” Magazine in 2003 and became the president of China’s M&A Elite Club in 2006. Hollyhigh has gathered many professional, experienced and motivated members in fields such as pharmaceutical investment, investment banks, finance and law. At present, it has more than 50 employees. 东方高圣的核心团队多数毕业于清华大学、北京大学药学院、中国药科大学、英国帝国理工大学等国内外著名学府。公司创始人陈明键先生毕业于清华大学经济管理学院,2003年被《英才》杂志评为最有影响力的投资银行家之一,2006年荣膺中国并购菁英俱乐部主席。东方高圣积聚了一批在医药投资、投资银行、财务、法律等领域职业素养高、有丰富实战经验、有交易情结的专业人才,员工总数超过50人。 In 2015, Hollyhigh accelerated the implementation of “Apollo Program” using ApolloBio(430187, a National Equities Exchange and Quotations [NEEQ] Company) as a platform. By raising funds of less than 3 billion yuan, it invests in new pharmaceuticals in phase III clinical trails in the United States and gains the exclusive rights to develop, produce and sell them in the Chinese market. It is a huge breakthrough in the Chinese biological medicine innovation model. 2015年,东方高圣以新三板公司东方略(430187, www.apollobio.com)为平台,全力推进“阿波罗计划”,通过募集不超过30亿元资金,投资美国临床三期的生物新药,获取中国市场的独家开发、生产、销售的权利,是中国生物医药创新模式的重大突破。